MAPK9 and osteosarcoma: While HGKshRNA was applied to knock down endogenous HGK expression in both of the osteosarcoma cells, it not only blocked HGK activation but also attenuated p-SAPK/JNK/p-c-Jun and SESN2 induction and LC3-II formation following TIIA treatment.